![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Biogen Idec, Abbott Announce Positive Top-Line Results From Registrational Trial for Daclizumab HYP in RRMS
Biogen Idec, Abbott Announce Positive Top-Line Results From Registrational Trial for Daclizumab HYP in RRMS
August 9, 2011
Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational Phase IIb clinical trial designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis (RRMS) over one year.
Financial Post
Financial Post
Upcoming Events
-
21Oct